Grifols | GRFS - Gross Profit On Sales

Stock Price
7.75
Daily Change
-0.12 -1.52%
Monthly
-17.55%
Yearly
-1.90%
Q1 Forecast
7.59

Grifols reported EUR766.49M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 190K 15.57M Sep/2025
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Immunic 0 0 Mar/2025
Infinity Pharmaceuticals USD 231K 59K Jun/2023
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 13.75M 650K Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
TherapeuticsMD USD 234K 79K Jun/2024